The estimated Net Worth of Gary S. Hogge is at least $1.33 Million dollars as of 11 February 2023. Gary Hogge owns over 13,020 units of Lineage Cell Therapeutics Inc stock worth over $11,265 and over the last 5 years he sold LCTX stock worth over $1,321,243. In addition, he makes $0 as Senior Vice President of Clinical & Medical Affairs at Lineage Cell Therapeutics Inc.
Gary has made over 2 trades of the Lineage Cell Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 13,020 units of LCTX stock worth $11,265 on 11 February 2023.
The largest trade he's ever made was selling 539,283 units of Lineage Cell Therapeutics Inc stock on 28 December 2021 worth over $1,321,243. On average, Gary trades about 78,900 units every 59 days since 2020. As of 11 February 2023 he still owns at least 13,020 units of Lineage Cell Therapeutics Inc stock.
You can see the complete history of Gary Hogge stock trades at the bottom of the page.
Dr. Gary S. Hogge Ph.D. serves as Senior Vice President of Clinical & Medical Affairs of the Company. Dr. Hogge has nearly 20 years of experience developing and supporting the commercialization of a number of products over a broad range of therapeutic areas. Dr. Hogge has held a variety of roles of increasing responsibility across multiple therapeutic areas in both clinical development and medical affairs. Previously Dr. Hogge was the Vice President of Medical Affairs at Questcor Pharmaceuticals, Inc. (QCOR) and before that held multiple leadership roles in both clinical development and medical affairs at Elan Pharmaceuticals including various responsibilities in the global clinical development of Tysabri® (natalizumab) in Crohn’s disease and multiple sclerosis, and for building and leading the medical affairs function. He served as medical director following the approval and launch of Tysabri. Prior to those accomplishments, he worked in clinical development for Ceplene® (histamine dihydrochloride) at Maxim Pharmaceuticals and in the immunology research and development group at Pfizer. Dr. Hogge obtained his B.S. degree and D.V.M. from Colorado State University, his M.S. and Ph.D. from the University of Wisconsin-Madison and was a visiting scientist at the Queensland Institute of Medical Research (QIMR) in Brisbane, Australia.
Gary Hogge is 52, he's been the Senior Vice President of Clinical & Medical Affairs of Lineage Cell Therapeutics Inc since 2019. There are 10 older and 6 younger executives at Lineage Cell Therapeutics Inc. The oldest executive at Lineage Cell Therapeutics Inc is Alfred Kingsley, 77, who is the Chairman of the Board.
Gary's mailing address filed with the SEC is 2173 SALK AVENUE, SUITE 200, , CARLSBAD, CA, 92008.
Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley, and Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.
biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include: